Vigonvita Life Sciences: Deloitte Affirms 2025 Connected Transactions Met Board Approval and Annual Caps

Bulletin Express05-25

Vigonvita Life Sciences Co., Ltd. (Vigonvita) announced that it has received a letter from its independent auditor, Deloitte Touche Tohmatsu, dated 22 May 2026, confirming the Group’s compliance with Listing Rule 14A.56 requirements for its 2025 continuing connected transactions.

According to Deloitte’s review, the Group’s purchases of active pharmaceutical ingredients (API) and related ancillary services during 2025:

1. Secured prior approval from Vigonvita’s Board of Directors. 2. Were executed, in all material respects, in accordance with the governing agreements. 3. Remained within the annual caps set out in the Company’s prospectus.

The Board further clarified that these transactions did not involve the provision of goods or services by Vigonvita to connected parties. Apart from the supplemental auditor confirmation, no other information in the Company’s 2025 Annual Report has been amended.

This announcement carries no impact on previously disclosed financial statements or other operational data. Vigonvita’s Board reiterated that all other disclosures in the Annual Report issued on 30 April 2026 remain unchanged.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148332748?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-25 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148332748","market":"hk","top_or_hot":-1,"title":"Vigonvita Life Sciences: Deloitte Affirms 2025 Connected Transactions Met Board Approval and Annual Caps","media":"Bulletin Express","content":"<p>Vigonvita Life Sciences Co., Ltd. (Vigonvita) announced that it has received a letter from its independent auditor, Deloitte Touche Tohmatsu, dated 22 May 2026, confirming the Group’s compliance with Listing Rule 14A.56 requirements for its 2025 continuing connected transactions.</p>\n<p>According to Deloitte’s review, the Group’s purchases of active pharmaceutical ingredients (API) and related ancillary services during 2025:</p>\n<p>1. Secured prior approval from Vigonvita’s Board of Directors.  \n2. Were executed, in all material respects, in accordance with the governing agreements.  \n3. Remained within the annual caps set out in the Company’s prospectus.</p>\n<p>The Board further clarified that these transactions did not involve the provision of goods or services by Vigonvita to connected parties. Apart from the supplemental auditor confirmation, no other information in the Company’s 2025 Annual Report has been amended.</p>\n<p>This announcement carries no impact on previously disclosed financial statements or other operational data. Vigonvita’s Board reiterated that all other disclosures in the Annual Report issued on 30 April 2026 remain unchanged.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vigonvita Life Sciences: Deloitte Affirms 2025 Connected Transactions Met Board Approval and Annual Caps</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVigonvita Life Sciences: Deloitte Affirms 2025 Connected Transactions Met Board Approval and Annual Caps\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-25 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vigonvita Life Sciences Co., Ltd. (Vigonvita) announced that it has received a letter from its independent auditor, Deloitte Touche Tohmatsu, dated 22 May 2026, confirming the Group’s compliance with Listing Rule 14A.56 requirements for its 2025 continuing connected transactions.</p>\n<p>According to Deloitte’s review, the Group’s purchases of active pharmaceutical ingredients (API) and related ancillary services during 2025:</p>\n<p>1. Secured prior approval from Vigonvita’s Board of Directors.  \n2. Were executed, in all material respects, in accordance with the governing agreements.  \n3. Remained within the annual caps set out in the Company’s prospectus.</p>\n<p>The Board further clarified that these transactions did not involve the provision of goods or services by Vigonvita to connected parties. Apart from the supplemental auditor confirmation, no other information in the Company’s 2025 Annual Report has been amended.</p>\n<p>This announcement carries no impact on previously disclosed financial statements or other operational data. Vigonvita’s Board reiterated that all other disclosures in the Annual Report issued on 30 April 2026 remain unchanged.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02630","symbol_name":"旺山旺水-B","start_time":0,"source_url":"","article_id":"1148332748","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148332748","pubTimestamp":1779704590,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Vigonvita Life Sciences Co., Ltd. (Vigonvita) announced that it has received a letter from its independent auditor, Deloitte Touche Tohmatsu, dated 22 May 2026, confirming the Group’s compliance with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02630":"旺山旺水-B"},"translate_title":"Vigonvita Life Sciences：德勤确认2025年关联交易符合董事会批准和年度上限","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02630":1},"content_text":"Vigonvita Life Sciences Co., Ltd. (Vigonvita) announced that it has received a letter from its independent auditor, Deloitte Touche Tohmatsu, dated 22 May 2026, confirming the Group’s compliance with Listing Rule 14A.56 requirements for its 2025 continuing connected transactions.\nAccording to Deloitte’s review, the Group’s purchases of active pharmaceutical ingredients (API) and related ancillary services during 2025:\n1. Secured prior approval from Vigonvita’s Board of Directors.  \n2. Were executed, in all material respects, in accordance with the governing agreements.  \n3. Remained within the annual caps set out in the Company’s prospectus.\nThe Board further clarified that these transactions did not involve the provision of goods or services by Vigonvita to connected parties. Apart from the supplemental auditor confirmation, no other information in the Company’s 2025 Annual Report has been amended.\nThis announcement carries no impact on previously disclosed financial statements or other operational data. Vigonvita’s Board reiterated that all other disclosures in the Annual Report issued on 30 April 2026 remain unchanged.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148332748","isCrawlerRequest":true}